GRM5 and Dyskinesia: While these compounds are currently in different testing phases, a few studies using adenosine A2A receptor antagonists and mGluR5 antagonists have demonstrated a significant reduction in dyskinesia induction in animal models [183,186,231] and subgroups of human samples [227,229,232].